SN-38

Name: SN-38
Brand: Selleck Chemicals
SKU: S4908
Rating: 5 (32 reviews)

For research use only.

Catalog No.S4908 Synonyms: NK012

32 publications

CAS No. 86639-52-3

SN-38 (NK012) is an active metabolite of CPT-11, inhibits DNA topoisomerase I, DNA synthesis and causes frequent DNA single-strand breaks. SN-38 induces autophagy.

Selleck's SN-38 has been cited by 32 publications

J Exp Clin Cancer Res, 2021, 40(1):15

PubMed: 33407715 ( click the link to review the publication )

Invest New Drugs, 2021, 10.1007/s10637-020-01003-3

PubMed: 33475937 ( click the link to review the publication )

Adv Sci (Weinh), 2020, 7(21):2001018

PubMed: 33173725 ( click the link to review the publication )

Small, 2020, 10.1002/smll.201906360

PubMed: 31972070 ( click the link to review the publication )

Int J Cancer, 2020, 10.1002/ijc.33393

PubMed: 33186476 ( click the link to review the publication )

Cell Death Dis, 2020, 11(9):773

PubMed: 32943619 ( click the link to review the publication )

Oncogenesis, 2020, 9(9):80

PubMed: 32908120 ( click the link to review the publication )

Invest New Drugs, 2020, 10.1007/s10637-020-01014-0

PubMed: 32981006 ( click the link to review the publication )

J Pharm Biomed Anal, 2020, 20;181:113073

PubMed: 31927166 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(7):2120-2127

PubMed: 32775005 ( click the link to review the publication )

Pharmacol Res, 2019, 148:104368

PubMed: 31415918 ( click the link to review the publication )

PLoS One, 2019, 14(10):e0224253

PubMed: 31648230 ( click the link to review the publication )

Oncotarget, 2019, 10(60):6403-6417

PubMed: 31741706 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 7(4):819-839

PubMed: 30831321 ( click the link to review the publication )

J Control Release, 2018, 275:85-91

PubMed: 29421609 ( click the link to review the publication )

Sci Signal, 2018, 11(540)eaat0229

PubMed: 30042127 ( click the link to review the publication )

Sci Rep, 2018, 8(1):15410

PubMed: 30337664 ( click the link to review the publication )

J Asian Nat Prod Res, 2018, 20(8):781-792

PubMed: 28679068 ( click the link to review the publication )

EMBO Mol Med, 2017, 9(3):293-303

PubMed: 28100566 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(22):6875-6887

PubMed: 28830922 ( click the link to review the publication )

Cancer Lett, 2017, 411:35-43

PubMed: 28964784 ( click the link to review the publication )

Free Radic Biol Med, 2017, 104:280-297

PubMed: 28131902 ( click the link to review the publication )

Cell Death Dis, 2017, 8(10):e3062

PubMed: 28981092 ( click the link to review the publication )

Biochem Pharmacol, 2017, 146:53-62

PubMed: 29031818 ( click the link to review the publication )
Int J Mol Med, 2017, 39(1):217-222

PubMed: 27878250 ( click the link to review the publication )

J Pediatr Hematol Oncol, 2017, 39(5):395-401

PubMed: 28562516 ( click the link to review the publication )

Oncotarget, 2017, 8(23):37394-37408

PubMed: 28445124 ( click the link to review the publication )

Assay Drug Dev Technol, 2016, 14(7):395-406

PubMed: 27552144 ( click the link to review the publication )

J Am Soc Mass Spectrom, 2015, 26(4):577-86

PubMed: ( click the link to review the publication )

J Am Soc Mass Spectrom, 2015, 26(4):577-86

PubMed: 25604392 ( click the link to review the publication )

PLoS One, 2015, 10(11):e0142704

PubMed: 26571493 ( click the link to review the publication )

J Pharmacol Exp Ther, 2014, 348(3):432-41

PubMed: 24361696 ( click the link to review the publication )

Purity & Quality Control

Choose Selective ADC Cytotoxin Inhibitors

Biological Activity

Description

SN-38 (NK012) is an active metabolite of CPT-11, inhibits DNA topoisomerase I, DNA synthesis and causes frequent DNA single-strand breaks. SN-38 induces autophagy.

Targets

Topo I ^[1]
(Cell-free assay)

In vitro

SN-38, a biological active metabolite of irinotecan hydrochloride (CPT-11). SN-38 causes the strongest inhibition of DNA topoisomerase I, followed by CPT and then CPT-11. CPT-11 dose dependently shifts the position of relaxed DNA in the direction of nicked DNA, but SN-38 and CPT shows no effect on the position of relaxed DNA. SN-38 dose-dependently and time-dependently inhibit DNA synthesis. Respective IC50 values of SN-38, in DNA synthesis is 0.077 μM. The inhibitory effect of SN-38 on RNA synthesis is less than that on DNA synthesis and it does not inhibit protein synthesis. SN-38 caused frequent DNA single-strand breaks in P388 cells. ^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
human DU145 prostate cell line	MXjQdo9tcW[ncnH0bY9vKGG\|c3H5			M{jNSmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iRGWxOFUheHKxc4TheIUh[2WubDDsbY5mNCCLQ{WwQVE{KG6P	NXS2OZR1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUC0PVgzOTZpPkGwOFk5OjF4PD;hQi=>
human MCF-7 breast cell line	MoTqVJJwdGmoZYLheIlwdiCjc4PhfS=>			NUftW2ZPSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2YuPyCkcnXhd5Qh[2WubDDsbY5mNCCLQ{WwQVAvOzdizszN	NFj6VmE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMES5PFIyPid-MUC0PVgzOTZ:L3G+
human SKOV-3 ovarian cell line	NGXkbmpRem:uaX\ldoF1cW:wIHHzd4F6			MWTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFONT2[tN{BwfmG{aXHuJINmdGxibHnu[UwhUUN3ME2wMlczKM7:TR?=	Ml35QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTB2OUiyNVYoRjFyNEm4NlE3RC:jPh?=
human breast cancer cell line (SK-BR-3)	MWnDfZRwfG:6aXRCpIF{e2G7			NGPR[nBKdiCYaYTyc{BkgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBjemWjc4SgZ4Fv[2W{IHPlcIwhdGmwZTCoV2suSlJvMzmsJGlEPTB;NDDuUS=>	MmTUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTF\|M{S1OlkoRjFzM{O0OVY6RC:jPh?=
human lung cancer cell line (H128)	M3nUOGN6fG:2b4jpZ:Kh[XO\|YYm=			M{jSVWlvKF[rdILvJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJIx2dmdiY3HuZ4VzKGOnbHygcIlv\SBqSEGyPEktKEmFNUC9OkBvVQ>?	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTN\|NEW2PUc,OTF\|M{S1Olk9N2F-
human stomach cancer cell line (MKN45)	M2C4RmN6fG:2b4jpZ:Kh[XO\|YYm=			MUPJckBXcXS{bzDjfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDzeI9u[WOqIHPhcoNmeiClZXzsJIxqdmViKF3LUlQ2MSxiSVO1NF05KG6P	NEC1PYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUOzOFU3QSd-MUGzN\|Q2Pjl:L3G+
human ovarian cancer cell line (SK-OV-3)	MYrDfZRwfG:6aXRCpIF{e2G7			M1;PNGlvKF[rdILvJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJI93[XKrYX6gZ4Fv[2W{IHPlcIwhdGmwZTCoV2suV1ZvMzmsJGlEPTB;MUGgcm0>	NHvodnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUOzOFU3QSd-MUGzN\|Q2Pjl:L3G+
human colon cancer cell line (WiDr)	NFPnb3lEgXSxdH;4bYPDqGG\|c3H5			M{n6SWlvKF[rdILvJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJINwdG:wIHPhcoNmeiClZXzsJIxqdmViKGfpSJIqNCCLQ{WwQVE1KG6P	M13Od\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzM{O0OVY6Lz5zMUOzOFU3QTxxYU6=
human lung cancer cell line (A549)	M1nnVmN6fG:2b4jpZ:Kh[XO\|YYm=			NF62NVhKdiCYaYTyc{BkgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBtfW6pIHPhcoNmeiClZXzsJIxqdmViKFG1OFkq	MnrqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTF\|M{S1OlkoRjFzM{O0OVY6RC:jPh?=
NSCLC-H460	MoHjR5l1d3SxeHnjxsBie3OjeR?=			NWjsNXV{S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hdm:wLYPtZYxtNWOnbHygcJVv\yClYYLjbY5wdWFiY3XscEBtcW6nIFi0OlAhME6VQ1zDMWg1PjBrLDDJR\|UxRThyIH7N	M1ThVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzNU[zPVI2Lz5zMUW2N\|kzPTxxYU6=
PC-3 carcinoma cell line	NIHP[Y5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=			MnTzR49v[2WwdILheIlwdiC{ZYH1bZJm\CC2bzDpcohq[mm2IHfyc5d1cCCxZjDoeY1idiCycn;zeIF1\SCSQz2zJINiemOrbn;tZUBk\WyuIHzpcoUtKEmFNUC9N\|UvPiCwTR?=	NFflUW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUS1OFI{OCd-MUW0OVQzOzB:L3G+
human HCT116 colon cancer cell line	NX3lOHo5TnWwY4Tpc44h[XO\|YYm=			NG\GOZpKdmirYnn0c5J6KGOxbnPlcpRz[XSrb36gZYdicW6\|dDDoeY1idiCKQ2SxNVYh[2:ub36gZ4Fv[2W{IHPlcIwhdGmwZTygTWM2OD15IH7N	NY\ifoJjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW4NFg1PTZpPkG1PFA5PDV4PD;hQi=>
human Bel-7402 liver cancer cell line	Mn;aSpVv[3Srb36gZZN{[Xl?			M1;D[WlvcGmkaYTvdpkh[2:wY3XueJJifGmxbjDh[4FqdnO2IHj1cYFvKEKnbD23OFAzKGyrdnXyJINidmOncjDj[YxtKGyrbnWsJGlEPTB;Mz6xPUDPxE1?	NFfDSZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUiwPFQ2Pid-MUW4NFg1PTZ:L3G+
human tumor HL60 cell-line	MlqySpVv[3Srb36gZZN{[Xl?		NEe3UWg{KGSjeYO=	NEH1SpBKdi24aYTyc{BqdmirYnn0c5J6KGOxbnPlcpRz[XSrb36g[o9zKGi3bXHuJJR2dW:{IFjMOlAh[2WubD3sbY5mKHejczDk[ZRmem2rbnXkJJV{cW6pIGPSRkBie3OjeTDh[pRmeiB\|IHThfZMhd2ZiaX7jeYJifGmxbjygTWM2OD1zOTDuUS=>	NVzCbopJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW5NVM6QTZpPkG1PVE{QTl4PD;hQi=>
human H460 cell	M{TDRmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			MWPJcohq[mm2aX;uJI9nKGi3bXHuJGg1PjBiY3XscEBoem:5dHisJGlEPTB;OECgcm0>	Ml60QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ7MUO3NFYoRjF4OUGzO\|A3RC:jPh?=
MDA-MB-435	NYrLXVlPTnWwY4Tpc44h[XO\|YYm=			MXfJcohq[mm2aX;uJIFo[Wmwc4SgUWRCNU2ELUSzOUBUKGi3bXHuJIJz\WG\|dDDjZY5k\XJiY3XscJMhcW5idHjlJIFje2WwY3Wgc4Yh[WykdX3pckwhUUN3MDC9JFAvODB3IN88UU4>	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTB3MkiwNkc,OTFyNUK4NFI9N2F-
MDA-MB-435	NY[wU4tbTnWwY4Tpc44h[XO\|YYm=			MkXFTY5pcWKrdHnvckBi\2GrboP0JG1FSS2PQj20N\|UhWyCqdX3hckBjemWjc4SgZ4Fv[2W{IHPlcIx{KGmwIITo[UBxemW\|ZX7j[UBw\iB\|MDDt[{9uVCCKU1GsJGlEPTBiPTCwMlA2KM7:TT6=	MoDUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTFyNUK4NFIoRjFzMEWyPFAzRC:jPh?=
PC-6/SN2-5H	NYHUNHpbTnWwY4Tpc44h[XO\|YYm=			NEHCXZBVWF:WUlHOV3BQWlSHUkqgeZB1[WunIHnuJI1mdWK{YX7lJJZme2mlbHWg[pJwdSCSQz22M3NPOi13SDDj[YxteyxiS32gQUA1KM7:TT6=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTZ6OEm4Nkc,OTF4OEi5PFI9N2F-
HT-29	Mn3uSpVv[3Srb36gZZN{[Xl?			NInQZplKdiC4aYTyc{BqdmirYnn0c5J6KGOxbnPlcpRz[XSrb36gdoVyfWm{ZXSgZYdicW6\|dDDIWE0zQSCqdX3hckBkd2yxbjDjZY5k\XJiY3XscJMtKEmFNUCgQUAxNjB{N{Og{txONg>?	M1y4blxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{NkG3PVI4Lz5zMk[xO\|kzPzxxYU6=
SaoS2	NETDS4pHfW6ldHnvckBie3OjeR?=			Mnz2WHBgXFKDTmPQU3JVTVJ8IHTyeYchemW\|aYP0ZY5k\SiLbXH0bY5q[iCvZYP5cIF1\SliaX6gRmNTWC2neIDy[ZN{cW6pIGPhc3MzKGOnbHzzMEBKSzVyIE2gNE4yPzZizszNMi=>	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTB3OUi4NUc,OTVyNUm4PFE9N2F-
DU145	NVnoU\|MySW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M1G4dFk3KGi{cx?=	MV;BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKESXMUS1JINmdGy\|IHHmeIVzKDl4IHjyd{whUUN3MDC9JFAvODB2IN88UU4>	MkL1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh{N{[xOFEoRjF6Mke2NVQyRC:jPh?=
MIA PaCa	NGPyZo9CdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NHXMcY46PiCqcoO=	MXTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2LQTDQZWNiKGOnbHzzJIFnfGW{IEm2JIhzeyxiSVO1NEA:KDBwMEC2JO69VS5?	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDJ5NkG0NUc,OTh{N{[xOFE9N2F-
HT29	NUDHOGpxSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M3nkNFk3KGi{cx?=	MnPWRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKVEK5JINmdGy\|IHHmeIVzKDl4IHjyd{whUUN3MDC9JFAvODF{IN88UU4>	M{jxclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6Mke2NVQyLz5zOEK3OlE1OTxxYU6=
H460	MlPwRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MljDNUBpeg>?	NYDZfGN5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIOFYxKGOnbHzzJIFnfGW{IEGgbJIhd2ZiZIL1[{BmgHCxc4Xy[UBu\WG\|dYLl[EBi\nSncjC3NkBpenNuIFnDOVAhRSByLkKyJO69VS5?	M3zxTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NEK0NVM{Lz5zOESyOFE{OzxxYU6=
HT29	MmPDRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M3zo[FEhcHJ?	M1zoXWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSGSyPUBk\WyuczDh[pRmeiBzIHjyJI9nKGS{dXeg[Zhxd3O3cnWgcYVie3W{ZXSgZYZ1\XJiN{KgbJJ{NCCLQ{WwJF0hOC54NzFOwG0v	NH\ZeYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOESyOFE{Oyd-MUi0NlQyOzN:L3G+
HT29	NUfpRlZrSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NGnMSIgyKGi{	NVvSfpE5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBDS1KSIH;2[ZJmgHC{ZYPzbY5oKG2rdH;4ZY51em:wZT3y[ZNqe3SjboSgbJVu[W5iSGSyPUBk\WyuczDh[pRmeiBzIHjyJI9nKGS{dXeg[Zhxd3O3cnWgcYVie3W{ZXSgZYZ1\XJiN{KgbJJ{NCCLQ{WwJF0hOTFwNTFOwG0v	NUXiPZdrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi0NlQyOzNpPkG4OFI1OTN\|PD;hQi=>
H460	NIG4VJhEgXSxdH;4bYNqfHliYYPzZZk>			NIjpNHFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJPDZyIHPlcIx{NCCLQ{WwJF0hOC5{MjFOwG0v	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDR\|NEG1N{c,OTh2M{SxOVM9N2F-
A549	MVvDfZRwfG:6aXPpeJkh[XO\|YYm=			NVH2SHFYS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCkeTDTVmIhdWW2aH;kMEBKSzVyIE2gNE4xQCEQvF2u	NYPiXVhQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi5PFY5ODdpPkG4PVg3QDB5PD;hQi=>
HT-29	Mnq3R5l1d3SxeHnjbZR6KGG\|c3H5			NIizSYREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJXC1{OTDj[YxteyCkeTDTVmIhdWW2aH;kMEBKSzVyIE2gNE4yOiEQvF2u	M3LX[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6OUi2PFA4Lz5zOEm4OlgxPzxxYU6=
PC6	MU\BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MUG2JIRigXN?	Moq2RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCSQ{[gZ4VtdHNiY3HydplqdmdicGLDJIFnfGW{IE[g[IF6eyxiSVO1NEA:KDBwMECwOFMh\|ryPLh?=	NVnlUohMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmyOVQ5PDNpPkG5NlU1QDR\|PD;hQi=>
HCT116	Ml\zRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MoDNN{Bl[Xm\|	NEDVbGpCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{Bi\nSncjCzJIRigXNuIFnDOVAhRSByLkCwNFU2KM7:TT6=	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTJ3NEi0N{c,OTl{NUS4OFM9N2F-
QG56	MYDBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NIj5fGI{KGSjeYO=	M1\xZmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUVe1OkBk\WyuczDh[pRmeiB\|IHThfZMtKEmFNUCgQUAxNjByMkig{txONg>?	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTJ3NEi0N{c,OTl{NUS4OFM9N2F-
NCI-H460	NIr5TGFCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NIjtTZc{KGSjeYO=	NXS3b2Q4SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOR2kuUDR4MDDj[YxteyCjZoTldkA{KGSjeYOsJGlEPTBiPTCwMlAxOzNizszNMi=>	M4jGeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MkW0PFQ{Lz5zOUK1OFg1OzxxYU6=
BCRP	MmXERY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NE[1VVQ3KGSjeYO=	M2fKVWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUFO2JIV5eHKnc4PpcochSkOUUDDj[YxteyCjZoTldkA3KGSjeYOsJGlEPTBiPTCwMlAxPTFizszNMi=>	M2qxXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MkW0PFQ{Lz5zOUK1OFg1OzxxYU6=
KB3-1	MkLsR5l1d3SxeHnjbZR6KGG\|c3H5		MnPvOEBl[Xm\|	NEfCV3ZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBMSjNvMTDj[YxteyCjZoTldkA1KGSjeYOgZpkhVVSWIH3leIhw\CxiSVO1NEA:KDBwMEC0JO69VS5?	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTNyM{OwOkc,OTl\|MEOzNFY9N2F-
KBV1	NFrQWpVEgXSxdH;4bYNqfHliYYPzZZk>		NXXJeG5NPCCmYYnz	MnKwR5l1d3SxeHnjbZR6KGGpYXnud5QhVUSUMTDveoVz\XiycnXzd4lv\yCqdX3hckBMSlZzIHPlcIx{KGGodHXyJFQh\GG7czDifUBOXFRibXX0bI9lNCCLQ{WwJF0hOC5yNE[g{txONg>?	NVfmNnJXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmzNFM{ODZpPkG5N\|A{OzB4PD;hQi=>
KBH5.0	MWfDfZRwfG:6aXPpeJkh[XO\|YYm=		NF3OU2E1KGSjeYO=	NUjK[VBSS3m2b4TvfIlkcXS7IHHnZYlve3RiQlPSVEBwfmW{ZYjwdoV{e2mwZzDoeY1idiCNQli1MlAh[2WubIOgZYZ1\XJiNDDkZZl{KGK7IF3UWEBu\XSqb3SsJGlEPTBiPTCwMlMh\|ryPLh?=	NEjpXXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUOwN\|MxPid-MUmzNFM{ODZ:L3G+
NCI-H460	NV3JWFg3SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MYqxJIhz	MmfQRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCQQ1mtTFQ3OCClZXzsd{Bi\nSncjDzbI9zfCC2ZYLtJIV5eG:\|dYLlJIZweiBzIHjyJI1m[XO3cnXkJIFnfGW{IEeyJIhzeyCrbjDkdpVoNW[{ZXWgcYVlcXWvLDDJR\|UxKD1iMD6xN{DPxE1w	M4nKUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NUOwO\|IxLz5zOUWzNFczODxxYU6=
A549/ATCC	NVfWemR6SW62aYT1cY9zKGG\|c3H5			NUfwXphZSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gRVU1QS:DVFPDJINmdGy\|IHL5JHNTSiCvZYToc4QtKEmFNUCgQUAxNjB6ODFOwG0v	NXX3eWloRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm1OFE1QDNpPkG5OVQyPDh\|PD;hQi=>
HT-29	M4fxeWFvfGm2dX3vdkBie3OjeR?=			MV7BcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKVD2yPUBk\WyuczDifUBUWkJibXX0bI9lNCCLQ{WwJF0hOC5zNzFOwG0v	NWjMUop6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm1OFE1QDNpPkG5OVQyPDh\|PD;hQi=>
gastric cancer cells	NXO1ZWU5T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MofFO\|IhcHK\|	M2m1W2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJIdie3S{aXOgZ4Fv[2W{IHPlcIx{KGGodHXyJFczKGi{czDifUB{fWyob4Loc4RidWmwZTDCJIF{e2G7LDDHTVUxKD1iMD6wOlYh\|ryPLh?=	NYDUUZVZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC4PFQxQDlpPkKwPFg1ODh7PD;hQi=>
lung cancer cells	MkLnS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M1zYNlczKGi{cx?=	MWDHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDseY5oKGOjbnPldkBk\WyuczDh[pRmeiB5MjDodpMh[nlic4Xs[o9zcG:mYX3pcoUhSiCjc4PhfUwhT0l3MDC9JFAvODZ4IN88UU4>	NFfQb2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEi4OFA5QSd-MkC4PFQxQDl:L3G+
colon cancer cells	NHvTZmpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MnfnO\|IhcHK\|	M2rGfGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJINwdG:wIHPhcoNmeiClZXzsd{Bi\nSncjC3NkBpenNiYomgd5Vt\m:{aH;kZY1qdmViQjDhd5NigSxiR1m1NEA:KDBwME[2JO69VS5?	Mnr6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB6OESwPFkoRjJyOEi0NFg6RC:jPh?=
HT-29	NFL6VVlEgXSxdH;4bYNqfHliYYPzZZk>			M1G2ZmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhVNTJ7IHPlcIx{NCCLQ{WwJF0hOC5yMEW5JO69VS5?	NFixVVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS3NFg3PCd-MkG0O\|A5PjR:L3G+
A549	MVvDfZRwfG:6aXPpeJkh[XO\|YYm=			MV;DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzMEBKSzVyIE2gNE4xPDdizszNMi=>	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR5MEi2OEc,OjF2N{C4OlQ9N2F-
PC3	NF61W2JEgXSxdH;4bYNqfHliYYPzZZk>		M3zKSFczKGi{cx?=	MXLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQR\|Mh[2WubIOg[ZhxemW\|c3nu[{BidHCqYUXi[ZRiOyCrboTl[5JqdiCjc4Pld5Nm\CCjczDj[YxtKHO3co\peoFtKGGodHXyJFczKGi{czDifUBUWkJiYYPzZZktKEmFNUCgQUAxNjByMk[g{txONg>?	NVH6d2FZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK5OVkzPDZpPkKyPVU6OjR4PD;hQi=>
A2780	MoflR5l1d3SxeHnjbZR6KGG\|c3H5		Mn;EO\|IhcHK\|	M2XDb2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGEzPzhyIHPlcIx{KG:4ZYLlfJBz\XO\|aX7nJIFteGijNXLleIE{KGmwdHXndolvKGG\|c3Xzd4VlKGG\|IHPlcIwhe3W{dnn2ZYwh[W[2ZYKgO\|IhcHK\|IHL5JHNTSiCjc4PhfUwhUUN3MDC9JFAvODB7IN88UU4>	MljhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ7NUmyOFYoRjJ{OUW5NlQ3RC:jPh?=
DU145	MUjDfZRwfG:6aXPpeJkh[XO\|YYm=			NGfJcllEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBFXTF2NTDj[YxteyxiSVO1NEA:KDBwMEOg{txONg>?	MoPsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3N{i1OFUoRjJ\|NUe4OVQ2RC:jPh?=
HT-29	NWLlXGNFS3m2b4TvfIlkcXS7IHHzd4F6			MW\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIWE0zQSClZXzsd{whUUN3MDC9JFAvODNizszNMi=>	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV5OEW0OUc,OjN3N{i1OFU9N2F-
L1210	M3vvNGN6fG:2b4jpZ4l1gSCjc4PhfS=>			MojxR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgUFEzOTBiY3XscJMtKEmFNUCgQUAxNjB2IN88UU4>	NITp[ms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W3PFU1PSd-MkO1O\|g2PDV:L3G+
DU145	Mn\mR5l1d3SxeHnjbZR6KGG\|c3H5		NXXRcZhuPzJiaILz	MUPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDEWVE1PSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJINmdGxidnnhZoltcXS7IHHmeIVzKDd{IHjyd{BjgSCPVGOgZZN{[XluIFnDOVAhRSByLkGxJO69VS5?	MoLmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MkK5PFEoRjJ\|NkKyPVgyRC:jPh?=
DU145	M3nX[2Z2dmO2aX;uJIF{e2G7	NFvaTWYxNjFidH:gNE42KHWP	NX\FbJhlOjRiaILz	NEH3SVBKdmirYnn0bY9vKG:oIFjERWMhcW5iaIXtZY4hTFVzNEWgZ4VtdHNiYYPz[ZN{\WRiYYOgeZBz\We3bHH0bY9vKG:oIICyNZdi\jFiZYjwdoV{e2mxbjDheEAxNjFidH:gNE42KHWPIHHmeIVzKDJ2IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm\|aYO=	NUHxfIdtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NlI6QDFpPkKzOlIzQThzPD;hQi=>
A549	M13s[mN6fG:2b4jpZ4l1gSCjc4PhfS=>		Mm[wN{Bl[Xm\|	MYDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIF{e2W\|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFMh\GG7czDifUBUWkJiYYPzZZktKEmFNUCgQUAxNjByMkeyJO69VS5?	MknuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3Mkm4O\|AoRjJ2NUK5PFcxRC:jPh?=
HCT116	NXzCcoRHS3m2b4TvfIlkcXS7IHHzd4F6		MXmzJIRigXN?	NFnYPItEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJS1RzMU[gZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiMzDkZZl{KGK7IGPSRkBie3OjeTygTWM2OCB;IECuNFMyKM7:TT6=	NIrUXXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEWyPVg4OCd-MkS1Nlk5PzB:L3G+
HT-29	M2mzd2N6fG:2b4jpZ4l1gSCjc4PhfS=>		MmDRN{Bl[Xm\|	NXXsZnVJS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUFRvMkmgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiMzDkZZl{KGK7IGPSRkBie3OjeTygTWM2OCB;IECuNVA3PjdizszNMi=>	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV{OUi3NEc,OjR3Mkm4O\|A9N2F-
HCT116	M1u3Z2N6fG:2b4jpZ4l1gSCjc4PhfS=>			Mn6zR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGNVOTF4IHPlcIx{NCCLQ{WwJF0hOC5zNk[g{txONg>?	M1Lue\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUK5PFcxLz5{NEWyPVg4ODxxYU6=
MDA-MB-231	MlnFR5l1d3SxeHnjbZR6KGG\|c3H5			NGrrZmFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtNlMyKGOnbHzzMEBKSzVyIE2gNE4yPzZizszNMi=>	M{fVblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUK5PFcxLz5{NEWyPVg4ODxxYU6=
A549	NWLIPXE{S3m2b4TvfIlkcXS7IHHzd4F6			NYXOcFQ6S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyxiSVO1NEA:KDBwMkW5JO69VS5?	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV{OUi3NEc,OjR3Mkm4O\|A9N2F-
HEK293	Mlq4R5l1d3SxeHnjbZR6KGG\|c3H5		MmO0O\|IhcHK\|	MXfJcpRzcW6\|aXOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhUEWNMkmzJINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiClZXzsJJZq[WKrbHn0fUBi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKTzVyIE2gNE4xODVizszNMi=>	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5MkC1OUc,OjV{N{KwOVU9N2F-
HCT116	MVrDfZRwfG:6aXPpeJkh[XO\|YYm=		NWm5V2NlPzJiaILz	NXTOc\|FKS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOWMUG2JINmdGy\|IHHmeIVzKDd{IHjyd{BjgSC\|dXzmc5Jpd2SjbXnu[UBDKGG\|c3H5MEBKSzVyIE2gNE4xODR{ODFOwG0v	M2jKPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEO1N\|U6Lz5{NUizOVM2QTxxYU6=
HT-29	NI\BeWhEgXSxdH;4bYNqfHliYYPzZZk>		Mn\aO\|IhcHK\|	NWXlNnVwS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUFRvMkmgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KHO3bH\vdohw\GGvaX7lJGIh[XO\|YYmsJGlEPTBiPTCwMlAyQDV2IN88UU4>	NGDhS4k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUizOVM2QSd-MkW4N\|U{PTl:L3G+
HCT15	MVXDfZRwfG:6aXPpeJkh[XO\|YYm=		NUmwOnZsPzJiaILz	MXTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3QyPSClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4OiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwJF0hOC5yMEig{txONg>?	M3X2NFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5ME[wO\|YxLz5{N{C2NFc3ODxxYU6=
U251	MX3DfZRwfG:6aXPpeJkh[XO\|YYm=		M3;xZVczKGi{cx?=	MVXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDVNlUyKGOnbHzzJIF{e2W\|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFczKGi{czDifUBUWkJiYYPzZZktKEmFNUCgQUAxNjB{MTFOwG0v	M17TXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5ME[wO\|YxLz5{N{C2NFc3ODxxYU6=
U87MG	M33tSWN6fG:2b4jpZ4l1gSCjc4PhfS=>		NH7yWpk4OiCqcoO=	MUPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDVPFdOTyClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4OiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwJF0hOC5yMzFOwG0v	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzB4MEe2NEc,OjdyNkC3OlA9N2F-
HT-29	MkO5R5l1d3SxeHnjbZR6KGG\|c3H5		MoL6O\|IhcHK\|	MV7DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIWE0zQSClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4OiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwJF0hOC5yNUSg{txONg>?	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzB4MEe2NEc,OjdyNkC3OlA9N2F-
MCF7	MYrDfZRwfG:6aXPpeJkh[XO\|YYm=		MlrQO\|IhcHK\|	M2HtdWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[XO\|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPzJiaILzJIJ6KFOUQjDhd5NigSxiSVO1NEA:KDBwNUG1JO69VS5?	M2\L[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5ME[wO\|YxLz5{N{C2NFc3ODxxYU6=
MDA-MB-231	MWfDfZRwfG:6aXPpeJkh[XO\|YYm=		MnzvO\|IhcHK\|	M1XtUmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj2yN\|Eh[2WubIOgZZN{\XO\|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44h[W[2ZYKgO\|IhcHK\|IHL5JHNTSiCjc4PhfUwhUUN3MDC9JFEvQTdizszNMi=>	M3jvN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5ME[wO\|YxLz5{N{C2NFc3ODxxYU6=
NCI-H460	MnzzR5l1d3SxeHnjbZR6KGG\|c3H5		MYSyOEBpenN?	NFjSS2JEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBPS0lvSES2NEBk\WyuczDwdoV1emWjdHXkJIZweiB{NDDodpMhfW6mZYKgco9zdW:6aXOgZ49v\Gm2aX;uJIZwdGyxd3XkJIJ6KGOxbYDveY5lKHejc3jveZQhdWWjc4Xy[YQh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvODVizszNMi=>	NYfHR3ZbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizOVA6QTdpPkK4N\|UxQTl5PD;hQi=>
NCI-H460	M3rBcWN6fG:2b4jpZ4l1gSCjc4PhfS=>		M3viOFI1KGi{cx?=	M2C4emN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG5EUS2KNE[wJINmdGy\|IIDy[ZRz\WG2ZXSg[o9zKDJ2IHjyd{B2dmSncjDofZBwgGmlIHPvcoRqfGmxbjDmc4xtd3enZDDifUBkd22yb4Xu[EB4[XOqb4X0JI1m[XO3cnXkJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlA3KM7:TT6=	M{DTZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{WwPVk4Lz5{OEO1NFk6PzxxYU6=
HT-29	MWXDfZRwfG:6aXPpeJkh[XO\|YYm=		M1i3d\|I1KGi{cx?=	M1vJe2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhVNTJ7IHPlcIx{KHC{ZYTy[YF1\WRiZn;yJFI1KGi{czD1coRmeiCwb4Ltc5hq[yClb37kbZRqd25iZn;scI94\WRiYomgZ49ueG:3bnSge4F{cG:3dDDt[YF{fXKnZDDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMj63OEDPxE1w	MnWzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh\|NUC5PVcoRjJ6M{WwPVk4RC:jPh?=
HT-29	Ml7PR5l1d3SxeHnjbZR6KGG\|c3H5		M{\rNVI1KGi{cx?=	NWTxbWpLS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUFRvMkmgZ4VtdHNicILleJJm[XSnZDDmc5IhOjRiaILzJJVv\GW{IHj5dI95cWNiY3;u[Il1cW:wIH\vcIxwf2WmIHL5JINwdXCxdX7kJJdie2ixdYSgcYVie3W{ZXSgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEOuO\|Eh\|ryPLh?=	M3PaUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{WwPVk4Lz5{OEO1NFk6PzxxYU6=
NCI-H460	NGXHOVdEgXSxdH;4bYNqfHliYYPzZZk>		NGDvfZM4OiCqcoO=	NGPxR45EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBPS0lvSES2NEBk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigdoVlfWO2aX;uJJVv\GW{IHj5dI95cWNiY3;u[Il1cW:wIHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkC0O{DPxE1w	NFv4VGg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEe0NFYyOyd-Mki3OFA3OTN:L3G+
NCI-H460	NFK0Um1EgXSxdH;4bYNqfHliYYPzZZk>		NUXC[FZzPzJiaILz	NFq1V\|NEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBPS0lvSES2NEBk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigdoVlfWO2aX;uJJVv\GW{IH7vdo1wgGmlIHPvcoRqfGmxbjDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6wOUDPxE1w	Mk\NQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh5NEC2NVMoRjJ6N{SwOlE{RC:jPh?=
HT-29	MXzDfZRwfG:6aXPpeJkh[XO\|YYm=		NXPobphZPzJiaILz	M4q4VGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhVNTJ7IHPlcIx{KGG\|c3Xzd4VlKGG\|IHfyc5d1cCC{ZXT1Z5Rqd25idX7k[ZIhdm:{bX;4bYMh[2:wZHn0bY9vKGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjB7NjFOwG0v	Mk\hQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh5NEC2NVMoRjJ6N{SwOlE{RC:jPh?=
HT-29	NUn3bZlxS3m2b4TvfIlkcXS7IHHzd4F6		Mm\hO\|IhcHK\|	NVP4VoVxS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUFRvMkmgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIILl[JVkfGmxbjD1coRmeiCqeYDvfIlkKGOxbnTpeIlwdiCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC5zMUmg{txONg>?	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDd2ME[xN{c,Ojh5NEC2NVM9N2F-
TC32	NIXRdFVyUFSVIHHzd4F6			NHr4bpVyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiVFOzNkBk\Wyucx?=	MmXmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
A673	MWXxTHRUKGG\|c3H5			MVTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[Yxtew>?	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
DAOY	MorvdWhVWyCjc4PhfS=>			M4rJbpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCGQV;ZJINmdGy\|	MnL1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Saos-2	MYXxTHRUKGG\|c3H5			NFvRZlRyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU3Hvd{0zKGOnbHzz	M4e0U\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-37	MXnxTHRUKGG\|c3H5			NX\4WHcxeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFLUMVM4KGOnbHzz	M{DaZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
RD	MVLxTHRUKGG\|c3H5			M{LQ[JFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCURDDj[Yxtew>?	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-SH	NXHPenc3eUiWUzDhd5NigQ>?			M3m3NZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMXNJKGOnbHzz	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
BT-12	MlyzdWhVWyCjc4PhfS=>			NFL4enVyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStNVIh[2WubIO=	M{DzTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R)	NH7WZmlyUFSVIHHzd4F6			NYTVbG43eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF3HJFY{KCh4LWTHJHIqKGOnbHzz	NFHldlg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB1643	NVX1eXJ3eUiWUzDhd5NigQ>?			M4njN5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQkG2OFMh[2WubIO=	MlXkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
OHS-50	MmCydWhVWyCjc4PhfS=>			NYXIW\|Z2eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF;IV{02OCClZXzsdy=>	NGDZWGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
BT-12	MX;xTHRUKGG\|c3H5			M2qy[ZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGJVNTF{IHPlcIx{	NV;NOYt3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh41	Mk\3dWhVWyCjc4PhfS=>			NH\FVZJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUni0NUBk\Wyucx?=	M1nM[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB-EBc1	M3jjNJFJXFNiYYPzZZk>			MknRdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgUmIuTUKlMTDj[Yxtew>?	M33LclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-SH	NGXab5ByUFSVIHHzd4F6			MX7xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDTT{1PNVOKIHPlcIx{	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh30	MWDxTHRUKGG\|c3H5			MWXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmh\|MDDj[Yxtew>?	MnK5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
A673	NFfMVJVyUFSVIHHzd4F6			M{\yWJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGE3PzNiY3XscJMq	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh30	MVnxTHRUKGG\|c3H5			NX7VfWtleUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhWmh\|MDDj[Yxtew>?	MkLxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
U-2 OS	Mnj3dWhVWyCjc4PhfS=>			NYXlell{eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhXS1{IF;TJINmdGy\|	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh41	MmLWdWhVWyCjc4PhfS=>			NGO1O3JyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBTcDRzIHPlcIx{	MmDKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2	MUPxTHRUKGG\|c3H5			NUfqV5hzeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPKMWdDVTJiY3XscJM>	Mn3JQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC	NGLN[\|hyUFSVIHHzd4F6			M4jue5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzz	MlH4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
NB-EBc1	M1rCVZFJXFNiYYPzZZk>			M1npb5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQj3FRoMyKGOnbHzz	MkK2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
LAN-5	NGL4ZY1yUFSVIHHzd4F6			NXewbIVreUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFzBUk02KGOnbHzz	NH3xeXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh18	NUG1[oFneUiWUzDhd5NigQ>?			NH\WWVhyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUnixPEBk\Wyucx?=	NY\mdpoxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
HCT116	MlHVRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M3G3b\|czKGi{cx?=	M37reGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDTVmIh[XO\|YYmsJGlEPTBiPTCwMlAxODd6IN88UU4>	M4W3flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMUG1OFkzLz5\|MEGxOVQ6OjxxYU6=
A549	NFTaTGVCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		Moq5O\|IhcHK\|	NVS2e\|FUSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDTVmIh[XO\|YYmsJGlEPTBiPTCwMlAxOTZ{IN88UU4>	NXq3[YZORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CxNVU1QTJpPkOwNVE2PDl{PD;hQi=>
MCF7	NH;teo1EgXSxdH;4bYNqfHliYYPzZZk>		NX\NZ44yPzJiaILz	MXPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHHzd4F6NCCLQ{WwJF0hOC5yMECxJO69VS5?	MnvTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzBzNkmwN\|goRjNyMU[5NFM5RC:jPh?=
A549	NFX0R2lEgXSxdH;4bYNqfHliYYPzZZk>		M4GydFczKGi{cx?=	NEOwbGZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPTR7IHPlcIx{KGGodHXyJFczKGi{czDifUB{fWyob4Loc4RidWmwZTDCJIF{e2G7LDDJR\|UxKD1iMD6yJO69VS5?	M4TKU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMU[5NFM5Lz5\|MEG2PVA{QDxxYU6=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-Chk1 / Chk1 / Topo I ; PubMed: 18509065 Mol Pharmacol Log-phase Ovcar-5 cells were treated for 24 h with diluent (0.1% DMSO, lanes 1 and 6), gemcitabine at 12.5, 25, 50 or 100 nM (lanes 2-5, respectively), or SN-38 at 2.5, 5, 10, 20 and 40 nM in the absence (lanes 7-11) or presence (lanes 12-17) of 50 nM gemcitabine. At the end of the incubation, whole cell lysates were prepared, subjected to SDS-PAGE, transferred to nitrocellulose, and probed with reagents that recognize phospho-Ser345-Chk1, total Chk1, topo I or, as control, β-actin. Because of the limited number of lanes on our electrophoresis apparatus, lanes 1-5 and 6-17 represent two different membranes from the same experiment that were probed simultaneously.	18509065
Growth inhibition assay	Cell viability; PubMed: 25759163 Mol Oncol (A) Drug sensitivity towards SN‐38 and oxaliplatin for the parental and drug resistant cell lines. Cells were exposed to a range of drug concentrations for 48 h and cell viability was assessed by an endpoint MTT assay. Results of representative experiments are shown. Green (triangle) is the parental cell line, blue (diamond) the SN‐38 resistant cell line, and red (square) the oxaliplatin resistant cell line.	25759163

In vivo

After oral dosing, peak SN-38 concentrations occurrs within 1 h, and the The percent unbound SN-38 lactone in murine plasma at 1000 ng/mL is 3.4 +/- 0.67%, whereas at 100 ng/mL the percent unbound is 1.18 +/- 0.14%. SN-38 lactone AUCs in micebearing human neuroblastoma xenografts are greater than in nontumor-bearing animals. ^[2]

Protocol

Kinase Assay:^[1]

- Collapse

Topoisomerase I Assay:

One unit (the minimum amount for full relaxation of 0.5 μg SV40 DNA under the conditions of this study) of topoisomerase I, 0.5 μL of the test compounds, and 0.5μg SV40 DNA are added sequentially to the reaction buffer, which is composed of 25 mM Tris-HCl (pH 7.5), 50 mM KC1, 5 mM MgCl₂, 0.25 mM EDTA disodium salt, 0.25 mM dithiothreitol, 15μg /mL bovine serum albumin, and 5% glycerol. Then, the reaction mixture (50 μL) is incubated for 10 min at 37 °C, and the reaction is terminated by treatment with 7.5 μL of a solution consisting of 1% sodium dodecyl sulfate, 20 mM EDTA disodium salt, and 0.5 mg/mL proteinase K for an additional 30 min at 37°C. The samples are mixed with 5 μL of the loading buffer containing 10 mM Na₂HPO₄, 31.3% sucrose, and 0.3% bromophenol blue. Relaxed (form Ir) DNA is separated from supercoiled (form I) and nicked (form II) DNA by electrophoresis on 0.8% agarose gel at 50 mA and 20 V for 17 h in the presence of 2 μg/mL chloroquine, 10 mM EDTA, 30 mM NaH₂PO₄, and 36 Mm Tris-HCl (pH 7.8). After electrophoresis, the gel is stained with 0.05% ethidium bromide and photographed with UV light (302 nm). The amount of DNA is quantified using a densitometer.

Cell Research:^[3]

- Collapse

Cell lines: A-172, U-87, and LA-567
Concentrations: 0 -1000 nM
Incubation Time: 48 h
Method: MTT assay
(Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	21 mg/mL (53.51 mM)
	Water	Insoluble
	Ethanol	Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download SN-38 SDF

Molecular Weight	392.4
Formula	C₂₂H₂₀N₂O₅
CAS No.	86639-52-3
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	NK012
Smiles	CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03964727	Suspended	Biological: IMMU-132	Metastatic Non-Small Cell Lung Carcinoma\|Head and Neck Squamous Cell Carcinoma\|Endometrial Cancer	Immunomedics Inc.	August 6 2019	Phase 2
NCT03995706	Recruiting	Drug: Sacituzumab Govitecan	Glioblastoma	The University of Texas Health Science Center at San Antonio\|Immunomedics Inc.	July 17 2019	Early Phase 1
NCT03245450	Recruiting	Drug: Eribulin mesilate\|Drug: Irinotecan hydrochloride	Refractory or Recurrent Solid Tumors\|Rhabdomyosarcoma\|Non-Rhabdomyosarcoma Soft Tissue Sarcoma\|Ewing Sarcoma	Eisai Inc.	February 22 2018	Phase 1\|Phase 2
NCT03221400	Recruiting	Drug: PEN-866 Sodium\|Drug: fluorouracil\|Drug: Folinic acid	Carcinoma\|Endometrial Adenocarcinoma\|Neoplasms\|Squamous Cell Carcinoma of the Anus\|Adenocarcinoma of the Pancreas\|Advanced Cancer\|Solid Tumor\|Solid Carcinoma\|Squamous Cell Carcinoma of the Cervix\|Squamous Cell Carcinoma\|Squamous Cell Carcinoma of the Vulva\|Squamous Cell Carcinoma of the Penis\|Gastric Cancer\|Gastric Adenocarcinoma\|Gastroesophageal Junction Adenocarcinoma\|Small-cell Lung Cancer\|Small Cell Lung Carcinoma\|Pancreatic Ductal Adenocarcinoma\|Pancreatic Adenocarcinoma	Tarveda Therapeutics	August 29 2017	Phase 1\|Phase 2
NCT03096340	Terminated	Drug: IT-141	Cancer\|Neoplasms\|Tumors\|Refractory Solid Tumors\|Recurrent Solid Tumors	Intezyne Technologies Inc.	March 23 2017	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Choose Your Country or Region

By Signaling Pathways

By product type

SN-38